Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide and Hydroxyurea Combination in Beta-Thalassemia
NCT06153784Phase 3Completed
- Sponsor
- National Institute of Child Health
- Start
- Jul 2020
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of thalidomide in beta thalassemia, sponsored by National Institute of Child Health. Primary endpoints: Response to Combination Therapy at 3 years, Change in Laboratory Levels at 3 years and 1 more. Started Jul 2020; status: completed.
02
Drugs
thalidomide
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06153784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06153784.